The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. (Q48933675)

17 February 2018

title

The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. (English)

1 reference

17 February 2018

author name string

Takanori Yamazaki

1

1 reference

17 February 2018

Naoto Yamashita

2

1 reference

17 February 2018

Yasukatsu Izumi

3

1 reference

17 February 2018

Yasuhiro Nakamura

4

1 reference

17 February 2018

Masayuki Shiota

5

1 reference

17 February 2018

Akihisa Hanatani

6

1 reference

17 February 2018

Kenei Shimada

7

1 reference

17 February 2018

Takashi Muro

8

1 reference

17 February 2018

Hiroshi Iwao

9

1 reference

17 February 2018

Minoru Yoshiyama

10

1 reference

17 February 2018

publication date

25 August 2011

1 reference

17 February 2018

published in

Hypertension Research

1 reference

17 February 2018

volume

35

1 reference

17 February 2018

issue

1

1 reference

17 February 2018

page(s)

34-40

1 reference

17 February 2018

https://scigraph.springernature.com/pub.10.1038/hr.2011.139

exact match

0 references

cites work

Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Pirfenidone: an anti-fibrotic therapy for progressive kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

New pharmacological treatments for improving renal outcomes in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Pirfenidone is renoprotective in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Pirfenidone: a potential therapeutic option in the treatment of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Inhibition of matrix deposition: a new strategy for prevention of restenosis after balloon angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Pirfenidone inhibits TGF-beta expression in malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Effects of metoprolol on epinephrine-induced takotsubo-like left ventricular dysfunction in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

The future of pharmacological therapy for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

TGF-beta signaling in vascular fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Chemokines and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Dominant-negative c-Jun inhibits rat cardiac hypertrophy induced by angiotensin II and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Ménage-à-trois 1 is critical for the transcriptional function of PPARgamma coactivator 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

Long-term administration of pirfenidone improves cardiac function in mdx mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

7 January 2021

Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

7 January 2021

Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

7 January 2021

Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

7 January 2021

Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

7 January 2021

Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

7 January 2021

Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2011.139

7 January 2021

Identifiers

DOI

10.1038/HR.2011.139

1 reference

17 February 2018

1 reference

17 February 2018